| Texto completo | |
| Autor(es): Mostrar menos - |
Roque-Borda, Cesar Augusto
;
Zhang, Qi
;
Nguyen, Thi Phuong Truc
;
Nguyen, Thi Thu Hoai
;
Medhi, Himadri
;
Rodrigues, Heitor Leocadio de Souza
;
Carnero, Christian S. Canales
;
Sutherland, Darcy
;
Helmy, Naiera M.
;
Araveti, Prasanna Babu
;
de la Torre, Beatriz G.
;
Albericio, Fernando
;
Pavan, Fernando Rogerio
Número total de Autores: 13
|
| Tipo de documento: | Artigo Científico |
| Fonte: | PHARMACOLOGICAL REVIEWS; v. 78, n. 1, p. 34-pg., 2026-01-01. |
| Resumo | |
Antimicrobial resistance represents one of the most pressing global health challenges of the 21st century, significantly compromising the efficacy of conventional antibiotics. In response to this crisis, the World Health Organization has updated its 2024 list of priority bacterial pathogens & horbar;classified into critical-, high-, and medium-risk groups & horbar;based on their resistance mechanisms, clinical impact, and global dissemination. This comprehensive review explores the emerging therapeutic potential of antimicrobial peptides (AMPs) when used in synergistic combinations with conventional antibiotics. By dissecting the mechanistic interplay & horbar;ranging from membrane disruption and efflux pump inhibition to biofilm penetration and intracellular antibiotic delivery & horbar;we provide a structured analysis of how these dual strategies overcome specific resistance barriers. Special emphasis is given to the World Health Organization-designated pathogens such as Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus (methicillin-resistant/vancomycin-resistant), Enterococcus faecium, Salmonella spp., Shigella spp., and Mycobacterium tuberculosis. Supported by extensive in vitro and in vivo data, this review catalogs dozens of successful AMP-antibiotic pairings, highlighting their fractional inhibitory concentration indices, clinical relevance, and implications for translational development. The evidence presented demonstrates that AMPs not only potentiate antibiotic action but also extend the useful lifespan of existing drugs while reducing toxicity. These findings support the advancement of AMP-based combination therapies as a next-generation strategy to contain resistance and restore the effectiveness of the antimicrobial arsenal. Significance Statement: Antimicrobial resistance remains a global health emergency, especially among World Health Organization 2024 priority pathogens. This review highlights the therapeutic promise of synergistic combinations between antimicrobial peptides and conventional antibiotics, offering a rational strategy to restore efficacy, overcome resistance mechanisms, and extend the clinical utility of existing drugs. By bridging microbiology, pharmacology, and translational medicine, this work provides timely insights for researchers and policymakers seeking innovative solutions to combat multidrug-resistant infections. (c) 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies. (AU) | |
| Processo FAPESP: | 20/16573-3 - Estudos in vitro e in vivo de análogos do peptídeo antimicrobiano B1CTcu5 encapsulados em micropartículas colón-específicas frente ao Mycobacterium tuberculosis |
| Beneficiário: | Cesar Augusto Roque Borda |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado |
| Processo FAPESP: | 24/23710-8 - Desenvolvimento e avaliação de novos bacPROTACs baseados em peptídeos antimicrobianos análogos ao CRDK22-s18G como agentes eficazes na degradação seletiva de proteínas em Mycobacterium tuberculosis |
| Beneficiário: | Cesar Augusto Roque Borda |
| Modalidade de apoio: | Bolsas no Brasil - Pós-Doutorado |
| Processo FAPESP: | 23/01664-1 - Síntese e caracterização de análogos do peptídeo antimicrobiano "B1CTcu5" encapsulados em micropartículas colón-específicas e estudos in vitro e in vivo frente ao Mycobacterium tuberculosis |
| Beneficiário: | Fernando Rogério Pavan |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 21/14603-5 - Descoberta e desenho de fármacos: análogos do peptídeo antimicrobiano B1CTcu5 promissores contra o Mycobacterium tuberculosis |
| Beneficiário: | Cesar Augusto Roque Borda |
| Modalidade de apoio: | Bolsas no Exterior - Estágio de Pesquisa - Doutorado |